ASP 7266Alternative Names: ASP7266
Latest Information Update: 26 Feb 2016
At a glance
- Originator Astellas Pharma
- Class Antiasthmatics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Asthma
Most Recent Events
- 26 Feb 2016 Phase-I clinical trials in severe Asthma in Japan (unspecified route) prior to January 2016 (Astellas Pharma pipeline, January 2016)